1	Combined	Combine	B-NP	VBN	O	6	NMOD	-1
2	topical	topical	I-NP	JJ	O	3	NMOD	-1
3	fluconazole	fluconazole	I-NP	NN	O	6	NMOD	-1
4	and	and	I-NP	CC	O	6	NMOD	-1
5	corticosteroid	corticosteroid	I-NP	NN	O	6	NMOD	-1
6	treatment	treatment	I-NP	NN	O	0	ROOT	19	treatment
7	for	for	B-PP	IN	O	6	NMOD	-1
8	experimental	experimental	B-NP	JJ	O	10	NMOD	-1
9	Candida	Candida	I-NP	NN	O	10	NMOD	-1
10	albicans	albican	I-NP	NNS	O	11	NMOD	-1
11	keratomycosis	keratomycosis	I-NP	NN	O	7	PMOD	-1
12	.	.	O	.	O	6	P	-1

1	PURPOSE	PURPOSE	B-NP	NN	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	To	To	B-VP	TO	O	4	VMOD	-1
4	determine	determine	I-VP	VB	O	1	NMOD	-1
5	the	the	B-NP	DT	O	11	NMOD	-1
6	most	most	I-NP	RBS	O	7	AMOD	-1
7	efficient	efficient	I-NP	JJ	O	11	NMOD	-1
8	time	time	I-NP	NN	O	9	NMOD	-1
9	point	point	I-NP	NN	O	11	NMOD	-1
10	and	and	O	CC	O	11	NMOD	-1
11	concentration	concentration	B-NP	NN	O	4	OBJ	-1
12	of	of	B-PP	IN	O	11	NMOD	-1
13	topical	topical	B-NP	JJ	O	14	NMOD	-1
14	corticosteroids	corticosteroid	I-NP	NNS	O	12	PMOD	-1
15	in	in	B-PP	IN	O	11	NMOD	-1
16	Candida	Candida	B-NP	NNP	O	18	NMOD	-1
17	albicans	albicans	I-NP	NNP	O	18	NMOD	-1
18	keratitis	keratitis	I-NP	NN	O	15	PMOD	-1
19	treated	treat	B-VP	VBN	O	18	NMOD	19	treated
20	with	with	B-PP	IN	O	19	VMOD	-1
21	fluconazole	fluconazole	B-NP	NN	O	20	PMOD	-1
22	.	.	O	.	O	4	P	-1

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	Corneas	Cornea	B-NP	NNS	O	7	SUB	-1
4	of	of	B-PP	IN	O	3	NMOD	-1
5	105	105	B-NP	CD	O	6	NMOD	-1
6	rabbits	rabbit	I-NP	NNS	O	4	PMOD	-1
7	were	be	B-VP	VBD	O	1	NMOD	-1
8	infected	infect	I-VP	VBN	O	7	VC	0
9	with	with	B-PP	IN	O	8	VMOD	-1
10	viable	viable	B-NP	JJ	O	12	NMOD	-1
11	yeast	yeast	I-NP	NN	O	12	NMOD	-1
12	cells	cell	I-NP	NNS	O	9	PMOD	-1
13	of	of	B-PP	IN	O	12	NMOD	-1
14	C.	C.	B-NP	FW	O	15	NMOD	-1
15	albicans	albicans	I-NP	FW	O	13	PMOD	-1
16	(	(	O	(	O	23	DEP	-1
17	2.5	2.5	B-NP	CD	O	19	NMOD	-1
18	x	x	I-NP	CC	O	19	NMOD	-1
19	10	10	I-NP	CD	O	23	DEP	-1
20	(	(	O	(	O	22	DEP	-1
21	5	5	B-NP	CD	O	22	DEP	-1
22	)	)	O	)	O	19	NMOD	-1
23	)	)	O	)	O	15	NMOD	-1
24	.	.	O	.	O	1	P	-1

1	After	After	B-PP	IN	O	11	VMOD	-1
2	a	a	B-NP	DT	O	5	NMOD	-1
3	48-hour	48-hour	I-NP	JJ	O	5	NMOD	-1
4	incubation	incubation	I-NP	NN	O	5	NMOD	-1
5	period	period	I-NP	NN	O	1	PMOD	-1
6	,	,	O	,	O	11	P	-1
7	seven	seven	B-NP	CD	O	8	NMOD	-1
8	groups	group	I-NP	NNS	O	11	SUB	-1
9	of	of	B-PP	IN	O	8	NMOD	-1
10	animals	animal	B-NP	NNS	O	9	PMOD	-1
11	were	be	B-VP	VBD	O	0	ROOT	-1
12	treated	treat	I-VP	VBN	O	11	VC	19	treated
13	for	for	B-PP	IN	O	12	VMOD	-1
14	21	21	B-NP	CD	O	15	NMOD	-1
15	days	day	I-NP	NNS	O	13	PMOD	-1
16	with	with	B-PP	IN	O	15	NMOD	-1
17	fluconazole	fluconazole	B-NP	NN	O	16	PMOD	-1
18	,	,	O	,	O	12	P	-1
19	with	with	B-PP	IN	O	12	VMOD	-1
20	group	group	B-NP	NN	O	19	PMOD	-1
21	I	I	I-NP	CD	O	20	NMOD	-1
22	acting	act	B-VP	VBG	O	12	VMOD	-1
23	as	as	B-PP	IN	O	22	VMOD	-1
24	a	a	B-NP	DT	O	25	NMOD	-1
25	control	control	I-NP	NN	O	23	PMOD	0
26	,	,	O	,	O	28	P	-1
27	and	and	O	CC	O	28	NMOD	-1
28	groups	group	B-NP	NNS	B-protein	11	VMOD	-1
29	II	II	B-NP	CD	I-protein	28	NMOD	-1
30	to	to	B-PP	TO	O	28	NMOD	-1
31	VII	VII	B-NP	CD	O	30	PMOD	-1
32	receiving	receive	B-VP	VBG	O	31	NMOD	0
33	adjunct	adjunct	B-NP	JJ	O	34	NMOD	-1
34	therapy	therapy	I-NP	NN	O	32	OBJ	19	therapy
35	with	with	B-PP	IN	O	34	NMOD	-1
36	the	the	B-NP	DT	O	38	NMOD	-1
37	corticosteroid	corticosteroid	I-NP	NN	O	38	NMOD	-1
38	prednisolone	prednisolone	I-NP	NN	O	35	PMOD	-1
39	(	(	O	(	O	55	DEP	-1
40	5	5	B-NP	CD	O	42	AMOD	-1
41	or	or	I-NP	CC	O	42	AMOD	-1
42	10	10	I-NP	CD	O	43	NMOD	-1
43	times	time	I-NP	NNS	O	52	NMOD	-1
44	daily	daily	I-NP	RB	O	43	NMOD	-1
45	;	;	O	:	O	52	P	-1
46	3	3	B-NP	CD	O	52	NMOD	-1
47	,	,	I-NP	,	O	52	P	-1
48	9	9	I-NP	CD	O	52	NMOD	-1
49	,	,	O	,	O	52	P	-1
50	or	or	O	CC	O	52	NMOD	-1
51	15	15	B-NP	CD	O	52	NMOD	-1
52	days	day	I-NP	NNS	O	55	DEP	-1
53	after	after	B-PP	IN	O	52	NMOD	-1
54	infection	infection	B-NP	NN	O	53	PMOD	0
55	)	)	O	)	O	31	NMOD	-1
56	.	.	O	.	O	11	P	-1

1	The	The	B-NP	DT	O	2	NMOD	-1
2	degree	degree	I-NP	NN	O	0	ROOT	-1
3	of	of	B-PP	IN	O	2	NMOD	-1
4	corneal	corneal	B-NP	JJ	O	5	NMOD	-1
5	infiltration	infiltration	I-NP	NN	O	21	SUB	14	infiltration
6	,	,	O	,	O	21	P	-1
7	ulceration	ulceration	B-NP	NN	O	21	SUB	-1
8	,	,	O	,	O	21	P	-1
9	corneal	corneal	B-NP	JJ	O	10	NMOD	-1
10	clouding	clouding	I-NP	NN	O	21	SUB	-1
11	,	,	O	,	O	21	P	-1
12	hypopyon	hypopyon	B-NP	NN	O	21	SUB	-1
13	,	,	O	,	O	21	P	-1
14	conjunctivitis	conjunctivitis	B-NP	NN	O	21	VMOD	-1
15	,	,	O	,	O	21	P	-1
16	neovascularization	neovascularization	B-NP	NN	O	21	SUB	3	neovascularization
17	,	,	O	,	O	21	P	-1
18	and	and	O	CC	O	21	VMOD	-1
19	corneal	corneal	B-NP	JJ	O	20	NMOD	-1
20	perforation	perforation	I-NP	NN	O	21	SUB	-1
21	was	be	B-VP	VBD	O	3	SBAR	-1
22	monitored	monitor	I-VP	VBN	O	21	VC	-1
23	over	over	B-PP	IN	O	22	VMOD	-1
24	a	a	B-NP	DT	O	26	NMOD	-1
25	24-day	24-day	I-NP	JJ	O	26	NMOD	-1
26	period	period	I-NP	NN	O	23	PMOD	-1
27	,	,	O	,	O	23	P	-1
28	as	as	B-CONJP	RB	O	23	DEP	-1
29	well	well	I-CONJP	RB	O	28	DEP	-1
30	as	as	I-CONJP	IN	O	28	DEP	-1
31	recultivation	recultivation	B-NP	NN	O	33	NMOD	-1
32	and	and	I-NP	CC	O	33	NMOD	-1
33	resistance	resistance	I-NP	NN	O	23	PMOD	-1
34	to	to	B-PP	TO	O	33	NMOD	-1
35	fluconazole	fluconazole	B-NP	NN	O	34	PMOD	-1
36	of	of	B-PP	IN	O	35	NMOD	-1
37	the	the	B-NP	DT	O	40	NMOD	-1
38	C.	C.	I-NP	FW	O	40	NMOD	-1
39	albicans	albicans	I-NP	FW	O	40	NMOD	-1
40	pathogen	pathogen	I-NP	NN	O	36	PMOD	-1
41	.	.	O	.	O	2	P	-1

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	-1
3	The	The	B-NP	DT	O	5	NMOD	-1
4	control	control	I-NP	NN	O	5	NMOD	0
5	group	group	I-NP	NN	O	6	SUB	-1
6	showed	show	B-VP	VBD	O	1	NMOD	-1
7	the	the	B-NP	DT	O	9	NMOD	-1
8	highest	high	I-NP	JJS	O	9	NMOD	-1
9	level	level	I-NP	NN	O	6	OBJ	-1
10	of	of	B-PP	IN	O	9	NMOD	-1
11	corneal	corneal	B-NP	JJ	O	12	NMOD	-1
12	clouding	clouding	I-NP	NN	O	14	NMOD	-1
13	and	and	I-NP	CC	O	14	NMOD	-1
14	neovascularization	neovascularization	I-NP	NN	O	10	PMOD	3	neovascularization
15	.	.	O	.	O	1	P	-1

1	In	In	B-PP	IN	O	16	VMOD	-1
2	comparison	comparison	B-NP	NN	O	1	PMOD	-1
3	,	,	O	,	O	16	P	-1
4	by	by	B-PP	IN	O	16	VMOD	-1
5	day	day	B-NP	NN	O	4	PMOD	-1
6	24	24	I-NP	CD	O	5	NMOD	-1
7	,	,	O	,	O	16	P	-1
8	the	the	B-NP	DT	O	9	NMOD	-1
9	majority	majority	I-NP	NN	O	16	SUB	-1
10	of	of	B-PP	IN	O	9	NMOD	-1
11	groups	group	B-NP	NNS	O	10	PMOD	-1
12	also	also	B-VP	RB	O	13	VMOD	-1
13	treated	treat	I-VP	VBN	O	11	NMOD	19	treated
14	with	with	B-PP	IN	O	13	VMOD	-1
15	prednisolone	prednisolone	B-NP	NN	O	14	PMOD	-1
16	displayed	display	B-VP	VBD	O	0	ROOT	-1
17	significantly	significantly	B-NP	RB	O	22	NMOD	-1
18	less	less	I-NP	RBR	O	17	AMOD	-1
19	corneal	corneal	I-NP	JJ	O	17	AMOD	-1
20	clouding	clouding	I-NP	NN	O	17	NMOD	-1
21	and	and	I-NP	CC	O	17	NMOD	-1
22	neovascularization	neovascularization	I-NP	NN	O	16	OBJ	3	neovascularization
23	.	.	O	.	O	16	P	-1

1	An	An	B-NP	DT	O	3	NMOD	-1
2	immediate	immediate	I-NP	JJ	O	3	NMOD	-1
3	decrease	decrease	I-NP	NN	O	7	SUB	0
4	in	in	B-PP	IN	O	3	NMOD	-1
5	corneal	corneal	B-NP	JJ	O	6	NMOD	-1
6	clouding	clouding	I-NP	NN	O	4	PMOD	-1
7	was	be	B-VP	VBD	O	0	ROOT	-1
8	observed	observe	I-VP	VBN	O	7	VC	0
9	in	in	B-PP	IN	O	8	VMOD	-1
10	groups	group	B-NP	NNS	O	9	PMOD	-1
11	treated	treat	B-VP	VBN	O	10	NMOD	19	treated
12	with	with	B-PP	IN	O	11	VMOD	-1
13	additional	additional	B-NP	JJ	O	16	AMOD	-1
14	low-	low-	I-NP	JJ	O	16	AMOD	-1
15	or	or	I-NP	CC	O	16	AMOD	-1
16	high-dose	high-dose	I-NP	JJ	O	17	NMOD	-1
17	prednisolone	prednisolone	I-NP	NN	O	12	PMOD	-1
18	from	from	B-PP	IN	O	10	NMOD	-1
19	day	day	B-NP	NN	O	18	PMOD	-1
20	9	9	I-NP	CD	O	19	NMOD	-1
21	after	after	B-PP	IN	O	8	VMOD	-1
22	inoculation	inoculation	B-NP	NN	O	21	PMOD	0
23	.	.	O	.	O	7	P	-1

1	After	After	B-PP	IN	O	16	VMOD	-1
2	additional	additional	B-NP	JJ	O	4	NMOD	-1
3	prednisolone	prednisolone	I-NP	NN	O	4	NMOD	-1
4	treatment	treatment	I-NP	NN	O	9	NMOD	19	treatment
5	from	from	B-PP	IN	O	4	NMOD	-1
6	day	day	B-NP	NN	O	5	PMOD	-1
7	9	9	I-NP	CD	O	6	NMOD	-1
8	or	or	I-NP	CC	O	9	NMOD	-1
9	15	15	I-NP	CD	O	1	PMOD	-1
10	after	after	B-PP	IN	O	9	NMOD	-1
11	inoculation	inoculation	B-NP	NN	O	10	PMOD	0
12	,	,	O	,	O	16	P	-1
13	no	no	B-NP	DT	O	15	NMOD	-1
14	significant	significant	I-NP	JJ	O	15	NMOD	-1
15	difference	difference	I-NP	NN	O	16	SUB	-1
16	was	be	B-VP	VBD	O	0	ROOT	-1
17	detected	detect	I-VP	VBN	O	16	VC	0
18	in	in	B-PP	IN	O	17	VMOD	-1
19	the	the	B-NP	DT	O	21	NMOD	-1
20	recultivation	recultivation	I-NP	NN	O	21	NMOD	-1
21	rate	rate	I-NP	NN	O	18	PMOD	-1
22	of	of	B-PP	IN	O	21	NMOD	-1
23	C.	C.	B-NP	NNP	O	24	NMOD	-1
24	albicans	albicans	I-NP	NNP	O	22	PMOD	-1
25	compared	compare	B-PP	VBN	O	17	VMOD	-1
26	with	with	B-PP	IN	O	25	PMOD	-1
27	the	the	B-NP	DT	O	28	NMOD	-1
28	control	control	I-NP	NN	O	26	PMOD	0
29	.	.	O	.	O	16	P	-1

1	Early	Early	B-NP	RB	O	2	NMOD	-1
2	administration	administration	I-NP	NN	O	14	SUB	19	administration
3	of	of	B-PP	IN	O	2	NMOD	-1
4	prednisolone	prednisolone	B-NP	NN	O	3	PMOD	-1
5	(	(	O	(	O	13	DEP	-1
6	day	day	B-NP	NN	O	12	NMOD	-1
7	3	3	I-NP	CD	O	6	NMOD	-1
8	,	,	O	,	O	12	P	-1
9	low	low	B-NP	JJ	O	12	NMOD	-1
10	and	and	I-NP	CC	O	12	NMOD	-1
11	high	high	I-NP	JJ	O	12	NMOD	-1
12	dose	dose	I-NP	NN	O	13	DEP	-1
13	)	)	O	)	O	2	NMOD	-1
14	resulted	result	B-VP	VBD	O	0	ROOT	0
15	in	in	B-PP	IN	O	14	VMOD	-1
16	the	the	B-NP	DT	O	17	NMOD	-1
17	recultivation	recultivation	I-NP	NN	O	15	PMOD	-1
18	of	of	B-PP	IN	O	17	NMOD	-1
19	significantly	significantly	B-NP	RB	O	20	AMOD	-1
20	more	more	I-NP	JJR	O	22	NMOD	-1
21	C.	C.	I-NP	NNP	O	22	NMOD	-1
22	albicans	albicans	I-NP	NNP	O	18	PMOD	-1
23	.	.	O	.	O	14	P	-1

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	9	VMOD	-1
2	:	:	O	:	O	1	P	-1
3	Fluconazole	Fluconazole	B-NP	NN	O	8	NMOD	-1
4	plus	plus	O	CC	O	8	NMOD	-1
5	adjunct	adjunct	B-NP	JJ	O	8	NMOD	-1
6	high-dose	high-dose	I-NP	JJ	O	8	NMOD	-1
7	prednisolone	prednisolone	I-NP	NN	O	8	NMOD	-1
8	treatment	treatment	I-NP	NN	O	9	SUB	19	treatment
9	was	be	B-VP	VBD	O	0	ROOT	-1
10	most	most	B-ADJP	RBS	O	11	AMOD	-1
11	effective	effective	I-ADJP	JJ	O	9	PRD	0
12	when	when	B-ADVP	WRB	O	9	VMOD	-1
13	administered	administer	B-VP	VBN	O	12	SBAR	0
14	9	9	B-NP	CD	O	15	NMOD	-1
15	days	day	I-NP	NNS	O	16	PMOD	-1
16	after	after	B-PP	IN	O	13	VMOD	-1
17	infection	infection	B-NP	NN	O	16	PMOD	0
18	.	.	O	.	O	9	P	-1

1	The	The	B-NP	DT	O	3	NMOD	-1
2	delayed	delay	I-NP	VBN	O	3	NMOD	0
3	application	application	I-NP	NN	O	16	SUB	19	application
4	of	of	B-PP	IN	O	3	NMOD	-1
5	corticosteroids	corticosteroid	B-NP	NNS	O	4	PMOD	-1
6	after	after	B-PP	IN	O	3	NMOD	-1
7	treatment	treatment	B-NP	NN	O	6	PMOD	19	treatment
8	with	with	B-PP	IN	O	7	NMOD	-1
9	antimycotic	antimycotic	B-NP	JJ	O	10	NMOD	-1
10	drugs	drug	I-NP	NNS	O	8	PMOD	-1
11	in	in	B-PP	IN	O	10	NMOD	-1
12	cases	case	B-NP	NNS	O	11	PMOD	-1
13	of	of	B-PP	IN	O	12	NMOD	-1
14	fungal	fungal	B-NP	JJ	O	15	NMOD	-1
15	keratitis	keratitis	I-NP	NN	O	13	PMOD	-1
16	is	be	B-VP	VBZ	O	0	ROOT	-1
17	therefore	therefore	I-VP	RB	O	16	VMOD	-1
18	not	not	I-VP	RB	O	16	VMOD	-1
19	contraindicated	contraindicate	I-VP	VBN	O	16	VC	-1
20	and	and	O	CC	O	16	VMOD	-1
21	may	may	B-VP	MD	O	16	VMOD	-1
22	be	be	I-VP	VB	O	21	VC	-1
23	beneficial	beneficial	B-ADJP	JJ	O	22	PRD	-1
24	in	in	B-PP	IN	O	22	VMOD	-1
25	patients	patient	B-NP	NNS	O	24	PMOD	-1
